Flexion Therapeutics Reports Second-Quarter 2018 Financial Results and Recent Business Highlights
Company reported net ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) sales of $3.8 million in Q2 representing 73% growth over Q1 Strong progress on the ZILRETTA commercial launch: 60% of target accounts have either purchased, or …